AR023564A1 - Una forma polimorfica de sal del acido maleico derivado del tiazolidina-2,4 diona, una composicion farmaceutica y el uso del mismo para la fabricacion deun medicamento - Google Patents
Una forma polimorfica de sal del acido maleico derivado del tiazolidina-2,4 diona, una composicion farmaceutica y el uso del mismo para la fabricacion deun medicamentoInfo
- Publication number
- AR023564A1 AR023564A1 ARP000101865A ARP000101865A AR023564A1 AR 023564 A1 AR023564 A1 AR 023564A1 AR P000101865 A ARP000101865 A AR P000101865A AR P000101865 A ARP000101865 A AR P000101865A AR 023564 A1 AR023564 A1 AR 023564A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacture
- pharmaceutical composition
- maleic acid
- provides
- polymorphic form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Una forma polimorfica de sal del ácido maleico de 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona, que: (i) proporciona un espectroinfrarrojo que contiene picos a 1360, 1326, 1241, 714 y 669 cm-1; y/o (ii) proporciona unespec tro Raman que contiene picos a 1.581, 768, 670, 271,, y 226-1y/o (iii) proporciona un espectro de resonancia magnética nuclear en estado solido que contiene picos a desplazamientos químicos sustancialmente como seestablecen en la Tabla I y/o(iv) pro porciona un patron de difraccion de rayos X a través de polvo (XRPD) que contiene picos sustancialmente que establecen enla tabla II; un procedimiento para preparar dicho compuesto, una composicion farmacéutica que contiene dicho compuesto,y el uso de dicho compuesto en para lafabricacion de un medicamento en medicina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9909472.4A GB9909472D0 (en) | 1999-04-23 | 1999-04-23 | Novel compounds |
GBGB9912197.2A GB9912197D0 (en) | 1999-05-25 | 1999-05-25 | Novel pharmaceutical |
Publications (1)
Publication Number | Publication Date |
---|---|
AR023564A1 true AR023564A1 (es) | 2002-09-04 |
Family
ID=26315460
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000101865A AR023564A1 (es) | 1999-04-23 | 2000-04-19 | Una forma polimorfica de sal del acido maleico derivado del tiazolidina-2,4 diona, una composicion farmaceutica y el uso del mismo para la fabricacion deun medicamento |
ARP000101870A AR023568A1 (es) | 1999-04-23 | 2000-04-19 | Un procedimiento para preparar una forma polimorfica de sal de acido maleico derivado de tiazolidina-2,4-diona |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000101870A AR023568A1 (es) | 1999-04-23 | 2000-04-19 | Un procedimiento para preparar una forma polimorfica de sal de acido maleico derivado de tiazolidina-2,4-diona |
Country Status (40)
Country | Link |
---|---|
US (2) | US6815457B1 (es) |
EP (3) | EP1903043A1 (es) |
JP (1) | JP2002543075A (es) |
KR (1) | KR100744359B1 (es) |
CN (1) | CN1208335C (es) |
AP (1) | AP1495A (es) |
AR (2) | AR023564A1 (es) |
AT (2) | ATE382046T1 (es) |
AU (1) | AU765498B2 (es) |
BG (1) | BG65427B1 (es) |
BR (1) | BR0009934A (es) |
CA (1) | CA2370258A1 (es) |
CO (1) | CO5170424A1 (es) |
CY (1) | CY1107238T1 (es) |
CZ (1) | CZ20013799A3 (es) |
DE (2) | DE60004658T2 (es) |
DK (2) | DK1173434T3 (es) |
DZ (1) | DZ3155A1 (es) |
EA (1) | EA004534B1 (es) |
ES (2) | ES2298327T3 (es) |
HK (2) | HK1045154B (es) |
HR (1) | HRP20010773B1 (es) |
HU (1) | HUP0200929A3 (es) |
IL (1) | IL146110A0 (es) |
MA (1) | MA26785A1 (es) |
MX (1) | MXPA01010820A (es) |
MY (1) | MY128007A (es) |
NO (1) | NO320589B1 (es) |
NZ (1) | NZ515163A (es) |
OA (1) | OA11871A (es) |
PE (1) | PE20010040A1 (es) |
PL (1) | PL351686A1 (es) |
PT (2) | PT1284268E (es) |
RS (1) | RS50114B (es) |
SK (1) | SK286423B6 (es) |
TR (1) | TR200103061T2 (es) |
TW (1) | TW591027B (es) |
UA (1) | UA67843C2 (es) |
UY (1) | UY26120A1 (es) |
WO (1) | WO2000064892A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6664278B2 (en) | 1997-12-16 | 2003-12-16 | Smithkline Beecham P.L.C. | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
GB9726568D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
US20020137940A1 (en) * | 1997-12-16 | 2002-09-26 | Smithkline Beecham P.L.C. | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
DK1173434T3 (da) | 1999-04-23 | 2003-12-08 | Smithkline Beecham Plc | Thiazolidindionderivat og dets anvendelse som antidiabetisk middel |
US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
PE20010044A1 (es) * | 1999-04-23 | 2001-03-10 | Smithkline Beecham Plc | Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona |
GB0006133D0 (en) | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
IL155036A0 (en) * | 2000-09-26 | 2003-10-31 | Reddy Research Foundation | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same |
US7241895B2 (en) * | 2000-09-26 | 2007-07-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
WO2003050116A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus |
AU2002352479A1 (en) * | 2001-12-20 | 2003-07-09 | Smithkline Beecham Plc | 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus |
GB0130511D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
GB0307259D0 (en) * | 2003-03-28 | 2003-05-07 | Glaxo Group Ltd | Process |
EP1468997A3 (en) * | 2003-04-18 | 2004-11-03 | CHEMI S.p.A. | Polymorphous forms of rosiglitazone maleate |
GB2405403A (en) * | 2003-08-29 | 2005-03-02 | Cipla Ltd | Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base |
EP1709038A2 (en) * | 2004-01-28 | 2006-10-11 | Usv Limited | A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate |
ITMI20041537A1 (it) * | 2004-07-28 | 2004-10-28 | Chemi Spa | Nuova forma polimorfa del rosiglitazone maleato |
CZ298424B6 (cs) * | 2005-05-24 | 2007-09-26 | Zentiva, A. S. | Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel |
US7435741B2 (en) * | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
US20090076093A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched rosiglitazone |
EP2184055A1 (en) | 2008-11-07 | 2010-05-12 | LEK Pharmaceuticals d.d. | Process for preparing solid dosage forms of rosiglitazone maleate |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288095B1 (en) | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
GB9124513D0 (en) | 1991-11-19 | 1992-01-08 | Smithkline Beecham Plc | Novel process |
GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
US5741803A (en) | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
US20010044458A1 (en) * | 1994-02-10 | 2001-11-22 | Smithkline Beechamp P.L.C. | Use of insulin sensitisers for treating renal diseases |
DE4404198A1 (de) | 1994-02-10 | 1995-08-17 | Henkel Kgaa | 2-Fluor-6-nitroaniline |
SG47100A1 (en) | 1994-02-10 | 1998-03-20 | Smithkline Beecham Plc | Use of insulin sensitisers for treating renal diseases |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
GB9711683D0 (en) | 1997-06-05 | 1997-08-06 | Smithkline Beecham Plc | Composition |
US20020028768A1 (en) * | 1997-06-18 | 2002-03-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with rosiglitazone and insulin |
KR20010013845A (ko) | 1997-06-18 | 2001-02-26 | 피터 기딩스 | 티아졸리딘디온 및 알파-글루코시다제 억제제를 사용한당뇨병의 치료 |
WO1998057649A1 (en) | 1997-06-18 | 1998-12-23 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and sulphonylurea |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
ATE355840T1 (de) | 1997-06-18 | 2007-03-15 | Smithkline Beecham Plc | Behandlung der diabetes mit thiazolidindione und metformin |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
GB9712866D0 (en) | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
US20020045649A1 (en) * | 1997-07-18 | 2002-04-18 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione and sulphonylurea |
GB9726568D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
GB9726563D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
US20020137940A1 (en) | 1997-12-16 | 2002-09-26 | Smithkline Beecham P.L.C. | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
GB9726566D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
PE20010044A1 (es) | 1999-04-23 | 2001-03-10 | Smithkline Beecham Plc | Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona |
DK1173434T3 (da) | 1999-04-23 | 2003-12-08 | Smithkline Beecham Plc | Thiazolidindionderivat og dets anvendelse som antidiabetisk middel |
WO2000064893A2 (en) | 1999-04-23 | 2000-11-02 | Smithkline Beecham Plc | Thiazolidinedione derivative and its use as antidiabetic |
IL155036A0 (en) | 2000-09-26 | 2003-10-31 | Reddy Research Foundation | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same |
-
2000
- 2000-04-19 DK DK00920889T patent/DK1173434T3/da active
- 2000-04-19 OA OA1200100275A patent/OA11871A/en unknown
- 2000-04-19 CZ CZ20013799A patent/CZ20013799A3/cs unknown
- 2000-04-19 EP EP07150378A patent/EP1903043A1/en not_active Withdrawn
- 2000-04-19 EA EA200101119A patent/EA004534B1/ru not_active IP Right Cessation
- 2000-04-19 JP JP2000614244A patent/JP2002543075A/ja active Pending
- 2000-04-19 DE DE60004658T patent/DE60004658T2/de not_active Expired - Fee Related
- 2000-04-19 AT AT02080320T patent/ATE382046T1/de not_active IP Right Cessation
- 2000-04-19 CN CNB008090572A patent/CN1208335C/zh not_active Expired - Fee Related
- 2000-04-19 EP EP00920889A patent/EP1173434B1/en not_active Expired - Lifetime
- 2000-04-19 AP APAP/P/2001/002333A patent/AP1495A/en active
- 2000-04-19 WO PCT/GB2000/001514 patent/WO2000064892A2/en not_active Application Discontinuation
- 2000-04-19 IL IL14611000A patent/IL146110A0/xx unknown
- 2000-04-19 RS YUP-752/01A patent/RS50114B/sr unknown
- 2000-04-19 DZ DZ003155A patent/DZ3155A1/xx active
- 2000-04-19 PT PT02080320T patent/PT1284268E/pt unknown
- 2000-04-19 SK SK1491-2001A patent/SK286423B6/sk not_active IP Right Cessation
- 2000-04-19 PE PE2000000364A patent/PE20010040A1/es not_active Application Discontinuation
- 2000-04-19 PT PT00920889T patent/PT1173434E/pt unknown
- 2000-04-19 TR TR2001/03061T patent/TR200103061T2/xx unknown
- 2000-04-19 CO CO00028932A patent/CO5170424A1/es not_active Application Discontinuation
- 2000-04-19 BR BR0009934-1A patent/BR0009934A/pt not_active Application Discontinuation
- 2000-04-19 UA UA2001117938A patent/UA67843C2/uk unknown
- 2000-04-19 PL PL00351686A patent/PL351686A1/xx not_active Application Discontinuation
- 2000-04-19 ES ES02080320T patent/ES2298327T3/es not_active Expired - Lifetime
- 2000-04-19 US US10/030,323 patent/US6815457B1/en not_active Expired - Fee Related
- 2000-04-19 CA CA002370258A patent/CA2370258A1/en not_active Abandoned
- 2000-04-19 DE DE60037602T patent/DE60037602T2/de not_active Expired - Fee Related
- 2000-04-19 AR ARP000101865A patent/AR023564A1/es unknown
- 2000-04-19 EP EP02080320A patent/EP1284268B1/en not_active Expired - Lifetime
- 2000-04-19 AR ARP000101870A patent/AR023568A1/es unknown
- 2000-04-19 KR KR1020017013557A patent/KR100744359B1/ko not_active IP Right Cessation
- 2000-04-19 NZ NZ515163A patent/NZ515163A/xx unknown
- 2000-04-19 DK DK02080320T patent/DK1284268T3/da active
- 2000-04-19 AT AT00920889T patent/ATE247653T1/de not_active IP Right Cessation
- 2000-04-19 HU HU0200929A patent/HUP0200929A3/hu not_active IP Right Cessation
- 2000-04-19 ES ES00920889T patent/ES2204557T3/es not_active Expired - Lifetime
- 2000-04-19 MX MXPA01010820A patent/MXPA01010820A/es unknown
- 2000-04-19 AU AU41306/00A patent/AU765498B2/en not_active Ceased
- 2000-04-21 MY MYPI20001707A patent/MY128007A/en unknown
- 2000-04-24 TW TW089107633A patent/TW591027B/zh not_active IP Right Cessation
- 2000-04-24 UY UY26120A patent/UY26120A1/es not_active Application Discontinuation
-
2001
- 2001-10-22 NO NO20015149A patent/NO320589B1/no unknown
- 2001-10-22 HR HR20010773A patent/HRP20010773B1/xx not_active IP Right Cessation
- 2001-10-22 MA MA26377A patent/MA26785A1/fr unknown
- 2001-11-20 BG BG106119A patent/BG65427B1/bg unknown
-
2002
- 2002-06-28 HK HK02104882.1A patent/HK1045154B/zh not_active IP Right Cessation
- 2002-06-28 HK HK03105903A patent/HK1055293A1/xx not_active IP Right Cessation
-
2003
- 2003-11-07 US US10/703,887 patent/US20040092555A1/en not_active Abandoned
-
2008
- 2008-03-12 CY CY20081100277T patent/CY1107238T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR023564A1 (es) | Una forma polimorfica de sal del acido maleico derivado del tiazolidina-2,4 diona, una composicion farmaceutica y el uso del mismo para la fabricacion deun medicamento | |
AR023561A1 (es) | Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento | |
HUP0300158A2 (en) | Hydrochloride salts of-5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, method for their production and pharmaceutical compositions containing them | |
CO4990943A1 (es) | Nuevo producto farmaceutico -n-(2-piridil)amino)etoxi]bencil]tiazolidin-2-4-diona | |
AR017214A1 (es) | Un proceso para preparar un hidrato de la sal del acido maleico de 5-[4[2-(n-metil-n-(2-piridil)amino)-etoxi]bencil]tiazolidin-2,4-diona | |
UY26119A1 (es) | Nuevo producto farmacéutico | |
UY25305A1 (es) | Hidrato de la sal del ácido maleico de la 5-[4-[2-(n-metil-n-2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona | |
EA200101101A1 (ru) | Новый фармацевтический препарат | |
CY1105354T1 (el) | Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο | |
AR023563A1 (es) | Monohidrato de hidrocloruro de un derivado de tiazolidin-2,4-diona, una composicion farmaceutica y el uso del mismo para la fabricacion de un medicamento | |
ECSP034505A (es) | La sal de clorhidrato de 5-[4-(2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2, 4-diona | |
ECSP034469A (es) | Compuesto farmaceutico novedoso | |
ECSP982780A (es) | Nuevo producto farmaceutico proceso para su preparacion y su uso en medicina | |
ECSP003434A (es) | Nuevos compuestos | |
ECSP982779A (es) | Un hidrato de la sal de acido maleico, proceso para la preparacion, composicion farmaceutica y su uso en medicina | |
ECSP003437A (es) | Nuevos compuestos | |
AP2002002684A0 (en) | 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical | |
TH84544A (th) | ไฮเดรทชนิดใหม่ | |
ECSP982781A (es) | Hidrato de la sal de maleico de 5-[4- (-n -metil-n- (2-piridil) amino) etoxi) bensil) tiazolidina - 2,4 diona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |